GSK’s Nucala Receives Health Canada’s Approval for Severe Eosinophilic Asthma in Children and Adolescents

 GSK’s Nucala Receives Health Canada’s Approval for Severe Eosinophilic Asthma in Children and Adolescents

GSK’s Nucala Receives Health Canada Approval for Severe Eosinophilic Asthma in Children and Adolescents

Shots:

  • Nucala (mepolizumab) has received Health Canada’s approval as an add-on maintenance therapy for adolescents & children aged ≥6yrs. with SEA
  •  The extension of NUCALA’s indication for adolescents and children aged ≥6yrs. allow the company to bring the therapy to patients and their families with limited treatment options
  • Nucala is the first IL5 biologic to be approved for SAE in a pediatric population (as young as 6 yrs. old) in Canada. The therapy has received approval in 20+ markets, including the US & EU for adult patients with SAE and indicated as an approved therapy for pediatric use in patients aged 6-17yrs. as an add-on treatment for SAE

Click here ­to­ read full press release/ article | Ref: Canada Newswire | Image: GSK

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post